Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.

In this study, irAEs was associated with a better outcome in patients treated with nivolumab for advanced NSCLC in the second line setting. Interestingly, the number of irAEs correlated with tumor response and PFS.
PMID: 32646604 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - July 5, 2020 Category: Cancer & Oncology Authors: Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, Mouroux J, Schiappa R, Padovani B, Hofman P, Otto J Tags: Bull Cancer Source Type: research